恩替卡韦、富马酸替诺福韦二吡呋酯和替诺福韦艾拉酚胺在

StephenW

恩替卡韦、富马酸替诺福韦二吡呋酯和替诺福韦艾拉酚胺在慢性乙型肝炎患者中的安全性和有效性的真实世界单中心比较
Sara Jeong 1 , Hyun Phil Shin 1 , Ha Il Kim 1
隶属关系
联系

    1
    韩国首尔江东庆熙大学医学院、庆熙大学医学院胃肠病学和肝脏病学系。

    PMID：34731856 DOI：10.1159/000519440

抽象的

简介：慢性乙型肝炎 (CHB) 是慢性肝病的主要原因，建议将富马酸替诺福韦酯 (TDF)、艾拉酚替诺福韦 (TAF) 和恩替卡韦 (ETV) 作为主要治疗药物。本研究旨在评估 ETV、TDF 和 TAF 在真实临床环境中的有效性和安全性。

方法：在这项回顾性队列研究中，共纳入 2007 年 7 月至 2019 年 9 月期间接受 ETV（n = 163）、TDF（n = 154）或 TAF（n = 46）治疗的 363 名 CHB 患者。

结果：患者年龄中位数为 51 岁，66.4% 的患者为男性。 ETV、TDF 或 TAF 治疗的中位持续时间为 49.0 个月（四分位距，27.0-74.0 个月）。在安全性方面，与基线相比，ETV 和 TAF 组的胆固醇轻度升高，而 TDF 组的胆固醇显着降低（p < 0.001）。 48 周时，3 组肝硬化相关并发症无显着差异（p = 0.235）。 48 周时乙型肝炎 e 抗原血清转化、完全病毒学应答和丙氨酸转氨酶正常化作为治疗效果的衡量标准在 3 组之间没有显着差异（分别为 p = 0.142、0.538 和 0.520）。 ETV 和 TDF 组之间的肝细胞癌 (HCC) 累积发病率也没有显着差异 (p = 0.894)。

结论：ETV、TDF 和 TAF 是安全的抗病毒药物，并且在 48 周时对 CHB 显示出相似的抗病毒效果。在 48 周的随访期内，ETV 和 TDF 组的肝硬化相关并发症和年 HCC 发病率没有显着差异。

关键词：慢性乙型肝炎；恩替卡韦；安全;替诺福韦；治疗结果。

© 2021 作者由巴塞尔 S. Karger AG 出版。

StephenW

Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B
Sara Jeong  1 , Hyun Phil Shin  1 , Ha Il Kim  1
Affiliations
Affiliation

    1
    Department of Gastroenterology and Hepatology, Kyung Hee University College of Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea.

    PMID: 34731856 DOI: 10.1159/000519440

Abstract

Introduction: Chronic hepatitis B (CHB) is a major cause of chronic liver diseases and tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and entecavir (ETV) are recommended as primary treatments. This study aimed to evaluate the efficacy and safety of ETV, TDF, and TAF in a real-world clinical setting.

Methods: In this retrospective cohort study, a total of 363 CHB patients who were treated with ETV (n = 163), TDF (n = 154), or TAF (n = 46) from July 2007 to September 2019 were enrolled.

Results: Median patient age was 51 years and 66.4% of patients were male. Median duration of treatment with ETV, TDF, or TAF was 49.0 months (interquartile range, 27.0-74.0 months). In terms of safety, cholesterol was mildly increased in the ETV and TAF groups and significantly lowered in the TDF group than baseline (p < 0.001). There was no significant difference in liver cirrhosis-related complications among the 3 groups at 48 weeks (p = 0.235). Hepatitis B e antigen seroconversion, complete virological response, and alanine aminotransferase normalization at 48 weeks as measures of treatment efficacy were not significantly different among the 3 groups (p = 0.142, 0.538, and 0.520, respectively). There was also no significant difference in cumulative incidence rate of hepatocellular carcinoma (HCC) between the ETV and TDF groups (p = 0.894).

Conclusions: ETV, TDF, and TAF were safe antiviral agents and showed similar antiviral effect for CHB at 48 weeks. Cirrhosis-related complications and annual HCC incidence rates did not differ significantly between the ETV and TDF groups over the 48 week follow-up period.

Keywords: Chronic hepatitis B; Entecavir; Safety; Tenofovir; Treatment outcome.

© 2021 The Author(s) Published by S. Karger AG, Basel.

StephenW

https://www.karger.com/Article/Pdf/519440